GIM
DGX icon

Glenmede Investment Management’s Quest Diagnostics DGX Stock Holding History

Glenmede Investment Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$17.2M Sell
90,031
-1,645
-2% -$292K 0.08% 214
2025
Q2 		$16.5M Buy
+91,676
New +$15.9M 0.08% 222

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Glenmede Investment Management's DGX Position: Q3 2025 in Review

Glenmede Investment Management reduced its Quest Diagnostics (DGX) stake by 1.8% in Q3 2025, selling an estimated $292K and leaving 90,031 shares worth $17.2M. The position accounts for 0.08% of the portfolio, ranked #214.

Glenmede Investment Management first reported a position in DGX in Q2 2025 and has held it in 2 quarters since. 1,005 funds tracked by Wall St. Rank hold DGX as of Q3 2025.

  • Glenmede Investment Management held 90,031 shares of Quest Diagnostics worth $17.2M as of Q3 2025.
  • Glenmede Investment Management sold 1,645 Quest Diagnostics shares in Q3 2025, an estimated $292K.
  • Quest Diagnostics made up 0.08% of Glenmede Investment Management's portfolio in Q3 2025, its #214 holding.
  • Glenmede Investment Management first reported a position in Quest Diagnostics in Q2 2025 and has held it in 2 quarters since.
  • 1,005 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.